Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

AR-101 (AerumabTM or 'Panobacumab') is fully human monoclonal lgM antibody directed against P. aeruginosa lipopolysaccharides (LPS) serotype O11. The LPS O11 serotype has a prevalence of approximately 22% of all P. aeruginosa hospital-acquired infections worldwide. AR-101's activity is based on its ability to bind and stimulate human complement deposition on P. aeruginosa, leading to improved immune cell recognition of the bacteria, and complement-dependent bacterial killing (its mechanism of action video is below). AR-101 is intended to be a first line adjunctive therapy for patients with severe P. aeruginosa pneumonia in hospital settings.


AR-101 has completed phase 1 in healthy volunteers and phase 2a clinical testing in hospital-acquired pneumonia (HAP) and ventilator- associated pneumonia (VAP) patients. The phase 2a preliminary proof-of-concept study evaluated AR-101 mAb in 18 very high risk HAP and VAP patients as an adjunctive therapy to standard of care antibiotics. The results showed that AR-101 met the primary safety endpoints, accelerated clinical cure of pneumonia, and protected all patients from mortality as compared to the contemporaneous standard of care antibiotics alone group [see [Que et al. Eur J Clin Micro. Inf. Dis. 2014]. This top-line preliminary result underscores the vast potential of anti-infective monoclonal antibody therapies as an adjunctive drug to complement standard of care antibiotics. AR-101 has been granted orphan drug designation in the US and EU. A multinational phase 2b double blinded placebo controlled clinical study of AR-101 in HAP/VAP patients is being planned.


Aridis has developed mAbs against the next two most prevalent and lethal LPS serotypes of P. aeruginosa (serO1 and serO6). Following the AR-101 product launch, the next product candidate will be a cocktail of AR-101 and mAbs to serotypes O6 and O1, which together will expand the coverage to more than half of all P. aeruginosa infections.   

AR-101: Fully Human mAb

Against Pseudomonas aeruginosa LPS serotype O11

AR-101 AerumabTM

AR-101 Mechanism of Action

PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis